NutriBand (NTRB) Depreciation & Amortization (CF) (2017 - 2026)
NutriBand (NTRB) posted Depreciation & Amortization (CF) of $34177.0 for Q2 2026, down 4.74% sequentially from $35879.0 in Q1 2026, and down 40.54% YoY from $57480.0 in Q2 2025.
NutriBand (NTRB) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
NutriBand has reported Depreciation & Amortization (CF) for 10 years, with the latest figure at $34177.0 in Q2 2026.
- Quarterly Depreciation & Amortization (CF) fell 40.54% year-over-year to $34177.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $170394.0 (down 37.68% YoY) and the FY2026 annual result came in at $193797.0, down 32.01% from the prior year.
- Depreciation & Amortization (CF) slipped to $34177.0 in Q2 2026 per NTRB's latest filing, from $35879.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $99779.0 in Q4 2022 and troughed at $34177.0 in Q2 2026.
- A 5-year average of $66897.4 and a median of $71402.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) rose 25.42% in 2022, then plunged 50.75% in 2026.
- Over 5 years, Depreciation & Amortization (CF) stood at $99779.0 in 2022, then sank by 31.98% to $67871.0 in 2023, then gained by 7.78% to $73149.0 in 2024, then sank by 41.28% to $42956.0 in 2025, then fell by 20.44% to $34177.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $34177.0, $35879.0, and $42956.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | NutriBand | 57.74 Mn | 53.73 Mn | 196,801.00 | 34,177.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 34,177.00 |
| Apr 30, 2026 | 34,177.00 |
| Jan 31, 2026 | 35,879.00 |
| Jan 31, 2026 | 35,879.00 |
| Oct 31, 2025 | 42,956.00 |
| Oct 31, 2025 | 42,956.00 |
| Jul 31, 2025 | 57,382.00 |
| Jul 31, 2025 | 57,382.00 |
| Apr 30, 2025 | 57,480.00 |
| Apr 30, 2025 | 57,480.00 |
| Jan 31, 2025 | 72,855.00 |
| Jan 31, 2025 | 72,855.00 |
| Oct 31, 2024 | 73,149.00 |
| Oct 31, 2024 | 73,149.00 |
| Jul 31, 2024 | 69,949.00 |
| Jul 31, 2024 | 69,949.00 |
| Apr 30, 2024 | 69,101.00 |
| Apr 30, 2024 | 69,101.00 |
| Jan 31, 2024 | 69,340.00 |
| Jan 31, 2024 | 69,340.00 |